NCT00967304 - Clinical Decision Rule Validation Study to Predict Low Recurrent Risk in Patients With Unprovoked Venous Thromboembolism | Biotech Hunter

Enrollment

2,779

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

January 31, 2015

Study Completion Date

July 31, 2016

Conditions

Idiopathic Venous Thromboembolism

Interventions

OTHER

"Application of theMen continue and HER DOO2 rule"

"Consecutive patients will have theMen continue and HER DOO2 rule applied by the attending physician between 5 - 12 months after treatment for a first unprovoked objectively proven major VTE.~Men continue and HER DOO2 rule: all men continue oral anticoagulants and women with 2 or more of the following features after 5-7 months of OAT should continue oral anticoagulants:1) HER - any Hyperpigmentation, Edema and Redness of either lower extremity, 2) Vidas D-dimer ≥250ug/L, 3) Obesity - BMI ≥30 kg/m2 and 4) Older age - Age ≥65 years."

Trial Locations (23)

27705

Duke University, Durham

Unknown

UC Davis, Santa Monica

Penobscot Bay Medical Center, Rockport

Prince of Wales Hospital, Sydney

CUB Hopital Erasme, Brussels

Hamilton Health Sciences Center, Hamilton

Hamilton Health Sciences Corporation, Hamilton

University Health Network, Toronto

Hopital Sacre Coeur, Montreal

McGill University Health Centre, Montreal

St. Mary's Hospital - CHUM, Montreal

Hopital Enfant Jesus, Québec

Centre Hospitalier Regional Universitaire de Brest, Brest

Orange Lifesciences, Nirmaya

Sahyadri Speciality Hospital, Pune

Shefali Centre, Shefali

Jashvant Patel Clinic, Surat

Hopitaux Universitaires de Geneve, Geneva

B3H2Y9

CDHA-Queen Elizabeth II Health Science Centre, Halifax

N6A 4G5

Victoria Hospital, London

K1Y 4E9

Ottawa Health Research Institute, Ottawa

H3T 1E2

SMBD Jewish General Hospital, Montreal

S7N 0W8

Saskatchewan Drug Research Institute, Saskatoon